Physician profile
Hetal Shah
NPI 1346287315
$691.41
in general payments reported to CMS, 2019-2025
18 companies · $73.44 in 2025
The $73.44 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.13 · 2020: $133 · 2021: $207 · 2022: $136 · 2023: $31.56 · 2024: $35.23 · 2025: $73.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $106.71 | 2019-2023 | Ubrelvy, Qulipta |
| Aspira Women'S Health INC | $104.66 | 2022 | |
| Ibsa Pharma INC. | $92.41 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.64 | 2020-2025 | Xifaxan, Trulance |
| Therapeuticsmd, INC. | $47.57 | 2019-2020 | |
| Astellas Pharma US INC | $47.51 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $30.15 | 2019-2022 | |
| Lilly USA, LLC | $30.05 | 2025 | Mounjaro, Zepbound |
| Lupin INC. | $25.34 | 2020 | |
| Mylan Pharmaceuticals INC. | $24.38 | 2021 | |
| Organon LLC | $23.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.62 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.13 | 2021 | |
| Amgen INC. | $16.87 | 2021 | |
| Roche Diagnostics Corporation | $15.15 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $14.42 | 2021 | |
| Vertical Pharmaceuticals, LLC | $12.10 | 2019 | |
| Gilead Sciences, INC. | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hetal Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.